Inclusion Criteria:  Patients with intermediate and high-risk AML who are diagnosed according to the 2016 WHO guidelines, aged ≥18 years; Detect minimal residual disease(-) after induction therapy and consolidation therapy; Eastern Cooperative Oncology Group (ECOG) performance status score 0-2;  The heart, pulmonary, liver and kidneys have sufficient organ functions:  Cardiac color doppler ultrasound shows cardiac ejection fraction> 50%, heart function classification NYHA III/IV, no heart block or arrhythmia; Patients without severe restrictive/obstructive pulmonary disease; Liver function: total bilirubin (TBIL) < 2 times the upper limit of normal, alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) <2.5 times the upper limit of normal; Renal function: serum creatinine (Cr) < 1.5 times the upper limit of normal. The patient and family members agree and sign an informed consent form.  Exclusion Criteria:  Patients with malignant tumors of other organs;  HCV positive; or HIV positive; or one of the following HBV test results:  HBsAg positive; HBsAg negative, HBcAb positive and HBV DNA titer positive; Pregnant and lactating women, and patients who have family planning during the enrollment period; Patients considered to be unsuitable for enrollment by the investigator.